Paragraph IV Patent Challenges: How Generic Makers Challenge Brands
Discover how generic drug manufacturers use Paragraph IV certifications to challenge brand-name patents under the Hatch-Waxman Act. Learn about the 180-day exclusivity, FDA approval timelines, and the economic impact on drug prices.
Read more